Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Fresenius completes €524 million sale of Fresenius Medical Care shares

By Public Technologies
  • Fresenius completed the sale of 13,400,000 Fresenius Medical Care shares at €39 per share, raising approximately €524 million in gross proceeds.
  • The sale reduced its stake to approximately 20% from approximately 25%.
  • Since deconsolidation, the holding has fallen from approximately 32%, generating cumulative gross proceeds of approximately €2.3 billion.
  • Net proceeds will be available for investment in growth platforms under the #FutureFresenius capital allocation priorities.
  • Settlement is expected on November 16, 2026, with the remaining shares subject to a 90-day lock-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2433360_en) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.